Estamos no ar no ! Saiba mais

Apollomics

APLM

Valor de mercado US$ 61,5 mi

21,10 USD

+0,10

0,48%

No fechamento Atualizado 16 de out. 16:00 EDT

1 dia

0,48%

5 dias

-0,33%

1 mês

-4,57%

3 meses

-9,33%

6 meses

51,8%

No acumulado do ano

9,33%

1 ano

-34,02%

5 anos

-99,28%

10 anos

-99,28%

Sobre: Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia. Company has three new immuno-oncology product candidates: APL-501, APL-502 and APL-801 include mono-specific and bi-specific antibodies to fight against cancer.

Funcionários: 15

Saúde Biotecnologia

Notícias

Positivo

Neutro

Negativo

Sentimento 3 meses

Positivo 0%

Neutro 100%

Negativo 0%

Apollomics Announces $10 Million Private Placement Transaction

FOSTER CITY, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM ) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced that it has entered into definitive subscription agreements (the “Subscription Agreements”) for a private placement transaction (the “Private Placement”) with certain accredited investors (the “Investors”), for an aggregate gross consideration of approximately $10.0 million. The Private Placement is expected to close on or about August 14, 2026, subject to the satisfaction of customary closing conditions.

Apollomics Announces $10 Million Private Placement Transaction

Apollomics Regains Full Compliance with Nasdaq Listing Requirements

FOSTER CITY, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM ) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced that on July 8, 2026, it received written notice from the Nasdaq Listing Qualifications Staff (Staff) stating that the Company regained compliance with the Market Value of Listed Securities (MVLS) requirement, as set forth in Nasdaq Listing Rule 5550(b)(2) (Rule) for continued listing on the Nasdaq Capital Market, and the matter is now closed.

Apollomics Regains Full Compliance with Nasdaq Listing Requirements

Apollomics Receives Nasdaq Deficiency Notice Regarding Minimum Market Value Requirement and Updates Rights for Vebreltinib (APL-101) in Asia

FOSTER CITY, Calif., June 24, 2026 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM ) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced that it has received a notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) dated June 18, 2026 stating that the Company is not in compliance with the requirement to maintain a minimum Market Value of Listed Securities (“MVLS”) of $35 million as set forth under Nasdaq Listing Rule for continued listing on The Nasdaq Capital Market.

Apollomics Receives Nasdaq Deficiency Notice Regarding Minimum Market Value Requirement and Updates Rights for Vebreltinib (APL-101) in Asia

Apollomics Reports Full Year 2025 Financial Results and Provides Clinical Updates and Business Progress

Phase 2 studies ongoing to advance global development of vebreltinib, a highly potent, de-risked and differentiated c-MET Inhibitor with best-in-class and first-in-class potential. To date, more than 600 patients and 170 healthy volunteers have been dosed with vebreltinib in clinical trials.

Apollomics Reports Full Year 2025 Financial Results and Provides Clinical Updates and Business Progress

Apollomics Inc. Announces $2.0 Million Bridge Financing

FOSTER CITY, Calif., April 01, 2026 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), today announced that it has entered into a $2.0 million unsecured Convertible Promissory Note (the “Note”) with Mr.

Apollomics Inc. Announces $2.0 Million Bridge Financing

Apollomics Reports First Half 2025 Financial Results

FOSTER CITY, Calif., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM ) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced financial results for the first half of 2025 ended June 30, 2025.

Apollomics Reports First Half 2025 Financial Results

Apollomics Announces Settlement of Cayman Litigation

FOSTER CITY, Calif., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”) (Nasdaq: APLM) announced today entering into a settlement agreement (the “Settlement Agreement” or the “Agreement”) with TWVC Goldlink Partners Investment Limited and TWVC Panglin Group Investment Limited (together, “TWVC”), entities represented by Triwise Capital Management Ltd, in connection with the litigation previously filed in the Grand Court of the Cayman Islands (the “Cayman Litigation”).

Apollomics Announces Settlement of Cayman Litigation

Apollomics Announces Changes to its Board of Directors and Composition of Committees

FOSTER CITY, Calif., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a California-based late-stage clinical biopharmaceutical company, today announced the following update regarding changes to the Company's board of directors (“Board”) and composition of committees.

Apollomics Announces Changes to its Board of Directors and Composition of Committees

Apollomics Announces Continued Listing on The Nasdaq Stock Market Following Hearing Cancellation

FOSTER CITY, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a California based late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, had previously announced that it had filed an application to appeal the delisting notification previously received from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market, LLC (“Nasdaq”) and request a hearing before a Nasdaq Hearings Panel to review the Staff's delisting determination.

Apollomics Announces Continued Listing on The Nasdaq Stock Market Following Hearing Cancellation

Apollomics Announces Continued Listing on The Nasdaq Stock Market Following Hearing Cancellation

FOSTER CITY, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a California based late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, had previously announced that it had filed an application to appeal the delisting notification previously received from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market, LLC (“Nasdaq”) and request a hearing before a Nasdaq Hearings Panel to review the Staff's delisting determination.

Apollomics Announces Continued Listing on The Nasdaq Stock Market Following Hearing Cancellation

Ver ranking de notícias

Gráficos de preços implementados com Lightweight Charts™